DIABOOST Professional Information

Complementary Medicine: Discipline Specific

This unregistered medicine has not been evaluated by the SAHPRA for its quality, safety or intended use.

SCHEDULING STATUS

S0

1. NAME OF MEDICINE

Diaboost tincture, oral drops

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each ml tincture contains:

Capsicum annuum L., (Cayenne) fruit powder	7.50 mg
Psidium guajava L., (guava), leaf extract (10:1)	10.00 mg
Vaccinium myrtillus L., (Bilberry) leaf powder	5.00 mg
Citrus Sinensis L. Osbeck (Orange) fruit extract standardised to 13% bioflavonoids	0.10 mg
Juglans nigra L. (Black walnut) hulls	5.00 mg
Apium graveolens L. (Celery) seed	..5.00 mg
Passiflora incarnata L. (Passionflower) flower	5.00 mg
Centella asiatica L. Urb. (Gotu Kola) herb	5.00 mg
Piper nigrum L. (Black pepper) fruit	0.50 mg
Zingiber officinale Roscoe (Ginger) root	0.50 mg

Contains ethanol: 50% v/v

Sugar free.

For full list of excipients, see section 6.1

3. PHARMACEUTICAL FORM

Liquid drops.

Yellow-brown liquid with characteristic herbal flavour and aroma.

4. CLINICAL PARTICULARS

4. 1 Therapeutic indications

Diaboost is a complementary medicine formulated to support healthy glucose metabolism and promote general wellbeing.

4. 2 Posology and method of administration

Posology

Adults: 20 – 30 drops in a little water, 3 times daily.

Children (12 years and older): 10 drops in a little water, 3 times daily.

Method of administration

For oral use.

4. 3 Contraindications

- Hypersensitivity to the active ingredients in **Diaboost** or to any of the excipients listed in section 6.1.
- Not to be taken during pregnancy and breastfeeding.
- Not recommended for children under the age of 12 years.

4. 4 Special warnings and precautions for use

Diaboost should be used with care in:

- Consult your health care provider before use if taking medication for blood sugar control
- Contains ethanol 50% (v/v). This should be taken into account in patients with alcoholism, individuals avoiding alcohol, hepatic impairment, epilepsy or other central nervous system disorders.
- Individuals with blood sugar concerns should consult a healthcare provider before use.
-

Paediatric population

Use in children under 12 years is contraindicated due to the ethanol content.

The ethanol exposure at the recommended dose is considered low and acceptable in adolescents aged 12 years and older.

4. 5 Interactions with other medicines and other forms of interactions

Diaboost may interact with the following medicines:

- Antidiabetic medicines
- Anticoagulants and antiplatelets medicines
- Aspirin
- Non-steroidal anti-inflammatory drugs (NSAIDs)
- ACE-inhibitors
- Antacids
- Ethanol content may enhance or modify the effects of sedatives and CNS depressants.

4. 6 Fertility, pregnancy and lactation

Use during pregnancy and lactation is not recommended.

No data are available on the effects on fertility.

4. 7 Effects on ability to drive and use machines

No studies on the effects on the ability to drive and use machinery have been performed.

Patients should exercise caution before driving or use of machinery until they are reasonably certain **Diaboost** does not adversely affect their performance.

May cause dizziness or drowsiness in sensitive individuals due to ethanol content.

4. 8 Undesirable effects

Diaboost is generally well tolerated, but side effects may occur:

System Organ Class	**Frequency Unknown**
Gastrointestinal disorders	Gastrointestinal irritation, heartburn
Central Nervous system disorders	Drowsiness, dizziness, sedation, impaired cognitive function
Skin and subcutaneous tissue disorders	Hypersensitivity reactions, dermatitis, rash

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicine is important. It allows continued monitoring of the benefit/risk balance of the medicine. Health care providers are asked to report any suspected adverse reactions to SAHPRA via the Med

Safety APP (Medsafety X SAHPRA) and eReporting platform (who-umc.org) found on SAHPRA website.

4. 9 Overdose

In overdose, side effects can be precipitated and/or be of increased severity (see section 4.8)

Treatment of overdose is symptomatic and supportive

5. PHARMALOGICAL PROPERTIES

5. 1 Pharmacodynamic properties:

Pharmacological Classification: Category D: Complementary Medicine: Discipline Specific

Pharmacotherapeutic group and ATC Code: D33.6 – Western Herbal Medicine

5. 2 Pharmacokinetic properties:

No pharmacokinetic studies have been performed on **Diaboost** as a combination product.

6. PHARMACEUTICAL PARTICULARS

6. 1 List of excipients

Ethyl alcohol 50% v/v

6. 2 Incompatibilities

Not applicable

6. 3 Shelf life

24 months

6. 4 Special precautions for storage

- Store at or below 30 ˚C.
- Protect from light and moisture.
- Do not use after the expiry date stated on the carton.
- Store in the original package.

6. 5 Nature and contents of the container

100 ml Yellow-brown liquid with characteristic herbal flavour and aroma, filled in an amber glass bottle with white tamper proof lid, packed in a carton.

6. 6 Special precautions for disposal of a used medicine or waste materials derived from such medicine and other handling of the product

No special requirement.

7. HOLDER OF THE CERTIFICATE OF REGISTRATION

Crux Pharmaceuticals (Pty) Ltd

630 Jacqueline Drive

Garsfontein

Pretoria

0042

Marketed by:

Nature life CC Trading as Naturelife SA

Unit 2, Blue, WOW Business Park,

Ballito

KZN

4390

8. REGISTRATION NUMBER(S):

To be allocated

9. DATE OF FIRST AUTHORISATION / RENEWAL OF THE AUTHORISATION

To be allocated

10. DATE OF REVISION OF THE TEXT

April 2026